How can RWD and AI transform drug development and strengthen value-based regulatory and HTA decision-making?
The 6th Nordic RWE and AI Conference, hosted by the University of Helsinki and Åbo Akademi University, explores these themes through a program highlighting collaboration, Nordic data excellence, methodological innovation, and real-world applications.
The Nordic RWE and AI conference brings together leading experts, researchers, and stakeholders to explore how RWD and AI can transform drug development, regulatory decision-making, and healthcare — with patient needs at the center. The goal is to highlight the Nordic region’s unique advantages, foster collaboration across academia, industry, and regulators, and accelerate value-based, patient-focused healthcare.
Venue: University of Helsinki, Main Building, Fabianinkatu 33, 00170 Helsinki, Finland – Auditorium and Agora Hall
Time: Tue 27 January 12.00-17.45 (networking event 18:30-19:30), Wed 28 January 9.00-15.30 (EET)
For more information contact Mia Bengtström.
The conference is free of charge to all participants—thanks to the support of the sponsors—though registration is required and a no-show fee applies. As participation is limited to 490 seats and the event is consistently highly popular, we encourage you to register early to secure your place. Please note that a separate registration is required for the networking event (networking event registration form can be found here).
Online remote attendance can be arranged for a fee of 500€. For more information contact Mia Bengtström.
The agenda will continue to be updated as we approach the seminar dates.
12.00 Registration, networking and exhibition in Agora Hall
13.00 Welcome, background and practicalities. Mia Bengtström Visiting Researcher, University of Helsinki and Associate professor, Åbo Akademi University
13.10 Value and drivers of clinical trials and RWD studies, Erkki Soini, Chairman of the Board, Health Economist. ESiOR Oy
13.30 AI-Driven Real-World Evidence: Unlocking Early Detection and Drug Repurposing in Dementia, Christian Jonasson, Research Director, NordicRWE
13.50 Fingenious® service and Finnish biobanks offer unique opportunities for biomedical research, Johanna Mäkelä, PhD, Director of Research and Services, FINBB
14.10 Unlocking the Power of RWE and AI for Cardiovascular Health: Insights from Helsinki, Riikka-Leena Leskelä, Research Director, Senior Partner, Nordic Healthcare Group
14.30 A Finnish Nationwide Register Study Describing People With and Without ADHD, Tuire Prami, Oriola
14.50 The Power of Three – A Tripartite Collaboration in Register Research, Katja Nolvi, Associate Director, Quantify Research
15.10 Coffee, exhibition and networking
16.00 Advancing Atherosclerotic Cardiovascular Disease (ASCVD) prevention through health and social data in Finland session by Novartis
16.45 FIREFLY: classifying induced vasomotor symptoms using RWD and natural language processing, Samu Kurki, Strategic Project Lead, Bayer
17.10 Session with Nordic Health Data Access Bodies
Moderator: Nicolas Vaugelade-Baust
Setting the scene: Navigating for health data – into the perfect storm? Michel Silvestri, The Swedish eHealth Agency
Short country overviews and moderated discussion with:
18.10 Thank you for the Day and walking to the City Hall
18.30- 19.30 The Networking Event hosted by the City of Helsinki
Join us for a networking reception at Helsinki City Hall (Pohjoisesplanadi 11–13). Capacity is limited to 220 participants.
Register—and cancel your registration if needed—by 20 January 2026: https://www.lyyti.fi/reg/reception27january. Registration confirmation is sent by email from edustus@hel.fi. Please present personal QR code ticket at entrance.
9.00 Welcome to Day 2, Mia Bengtström and chair Riikka-Leena Leskelä, Research Director, Nordic Healthcare Group
9.05 External Control Arms in Regulatory and HTA Decision-Making, session by MedEngine
Host: Karin Luttropp, Senior Advisor – Real World Evidence NE Hub, Eli Lilly
10.05 Transportability and External Validity: Approaches to Generalizing Evidence, Iiro Toppila Data Analysis Lead, Medaffcon
10.30 Real-world data enabling VBHC transformation at HUS Psychiatry session by HUS, University of Helsinki, Johnson & Johnson
11.10 Coffee, light lunch, networking Agora Exhibition Hall
11.50 Value of Patient Experience Data When Addressing Nordic Stakeholders’ Needs session by IQVIA
12.20 Strengthening Confidence in RWE for Assisted Reproductive Technology: Merck KGaA’s Commitment to Scientific Rigor, Lise Braathen-Pettersen, Global Medical Director Fertility, Merck Healthcare
12.45 Transforming Patient Pathways: AI-Driven Risk Prediction and Cross-Sector Optimization in Cardiovascular Care, Jesper Eriksen, Head of Data Analytics, Healthcare Nordics, IQVIA
13.05 The Journey from Care to Evidence: Tackling Registry Hurdles, Hanna Heloterä, Senior Consultant, Pharmaca Health Intelligence Oy
13.25 Coffee and networking Agora Exhibition Hall
14.10 Next-Generation Anonymization: Securing Nordic RWD for Cross-Border AI & RWE Innovation, Tuomo Pentikäinen, CEO of VEIL.AI
14.30 Bright Future for the use of RWE and AI in the Nordic Region for the best of the Patients, Society and Economy: Visionary moderated discussion on using the excellent RWD assets in the Nordic Region to improve Drug development, Value-based Decision Making and Healthcare
Moderator: Lisse-Lotte Hermansson, Managing Director at Medaffcon AB Sweden
Setting the scene: Olli Kallioniemi, Research Director at the Institute for Molecular Medicine Finland (FIMM) presenting findings from Sitra’s project A plan for the Finnish Health Data Space (FHDS) in the AI-era.
15.20-15.30 Next steps. Thank you for participating and funding, Mia Bengtström
The conference is free of charge but requires registration. Cancellation policy; cancellation done by 19 January 2026 is free of charge. After 19th January 2025, the invoiceable per individual cancellation fee is 100.00€ per day of the event, and 80.00€ per individual for the separate networking event.
A large proportion of patients with psoriasis need to switch biologic treatment after initiation. This finding emerges from two RWE studies focusing on plaque psoriasis and psoriatic arthritis.
The reform of the Secondary Use Act will establish a new decentralised process, in parallel to the current centralised permit model in which Findata grants all data permits.
As we approach the end of 2025 and prepare to slow down for the holidays, I want to take a moment to reflect on an exceptional year for Medaffcon—one defined by growth and expansion.